Arrevus Gets Support from NC Biotech Center to Advance ARV-1801 for Pulmonary Exacerbations in CF
Arrevus received a Small Business Research Loan from the North Carolina Biotechnology Center to support the development of the company’s Phase 3 therapeutic candidate ARV-1801 for the treatment of pulmonary exacerbations in patients with cystic fibrosis (CF). The Small Business Research Loan program grants investments of $75,000—$250,000…